Point of Care Coagulation Testing Products Market Size & Share 2025 - 2034

Point of Care Coagulation Testing Products Market Size

The global point of care coagulation testing products market was estimated at USD 2.8 billion in 2024. The market is expected to grow from USD 3.1 billion in 2025 to USD 5.2 billion by 2034 at a CAGR of 6.2% during the forecast period.

Point-of-care coagulation testing products are a type of medical devices which are designed to rapidly assess blood clotting at the point of care, apart from traditional laboratory settings. They provide rapid and accurate coagulation information, which helps in making immediate clinical decisions during surgeries, emergencies, and ongoing chronic care.
 

The global point of care coagulation testing products market is witnessing substantial growth, fueled by the increasing prevalence of chronic blood disorders. For instance, in 2022, data from the World Bleeding Disorders Registry (WBDR) reported that among 11,374 individuals suffered with hemophilia across 115 treatment centers in 44 countries, among them only 30% of adults and 32% of children with severe hemophilia received prophylactic treatment. Thus, these statistics highlight the need for better access to point-of-care coagulation testing products to enable the early detection, better disease management, and increased availability of preventive treatment for individuals suffering from hemophilia and other chronic blood disorders.
 

Additionally, technological advancements in point of care (POC) coagulation testing products focuses on improving accuracy, speed, and easy use through miniaturization, automation, and connectivity. Modern innovated devices are now integrated with new technologies such as microfluidic technology, biosensors, which is estimated to reach USD 58.5 billion by 2032 and advanced optical or electrochemical detection methods to provide rapid and consistent results with minimal blood sample requirements.
 

For example, Roche’s CoaguChek systems, allow patients to monitor their blood clotting levels at home with minimal effort. AI-driven analytics improve diagnostic precision, while wireless connectivity and cloud integration support real-time data sharing with healthcare providers. Moreover, growing government initiatives to curb blood-related diseases and increasing adoption of point of care testing products, are propelling market growth.
 

Point of Care Coagulation Testing Products Market Trends

• The growing global focus on early detection and management of blood-related disorders are driving significant advancements and investments in point-of-care coagulation testing products.
   
• Governments are prioritizing early detection of blood-related diseases to minimize healthcare burdens, driving with initiatives such as research funding, awareness campaigns for point-of-care coagulation testing products.
   
• For instance, in March 2022, the National Hemophilia Foundation launched the "Starts the Conversation" initiative for bleeding disorders awareness month. This initiative was designed to spotlight a diverse spectrum of experiences, involving disease conditions, research pursuits, educational campaigns, and advocacy efforts.
   
• Furthermore, the U.S. continues to focus on research and innovation in blood disorder treatments, with substantial investments which is aimed at improving patient outcomes. For example, the National Bleeding Disorders Foundation (NBDF) has invested over USD 22 million in research aimed at eliminating bleeding disorders.
   
• Moreover, collaborations between the government and private sector companies have been involved in advancing POC diagnostics. These partnerships focus on developing new innovative technologies that support direct testing and diagnosis, thereby improving access to essential healthcare services.
   
• Thus, these initiatives and investment continues, the market is poised to experience significant growth in the upcoming years.
   

Point of Care Coagulation Testing Products Market Analysis

Based on test type, the market is segmented into prothrombin time testing products, activated clotting time (ACT/APTT) testing products, platelet count, d-dimer test, and others test types. The market accounted a revenue of USD 2.6 billion in 2023. The prothrombin time testing products segment is accounted for a significant revenue of USD 1 billion in 2024 and the segment is poised for significant growth at a CAGR of 6.3% during the forecast period.
 

• Prothrombin time (PT) testing products offers a quick and accurate results within minutes, which allows healthcare professionals to make timely medical decisions. This is especially important for patients require anticoagulants therapy, as delays in monitoring can increase the risk of bleeding or clotting complications. For example, the Abbott i-STAT PT/INR system provides results in just two minutes, which enables immediate decision-making in emergency cases.
   
• Additionally, new innovated PT testing devices only needs a small capillary blood sample, which makes them less invasive and more comfortable compared to traditional venous blood draws. Many of such devices are designed for easy use, enabling both healthcare professionals and patients to operate them with minimal training.
   
• Furthermore, point-of-care PT testing products are compact, lightweight, and wireless, making them accessible for home use, remote monitoring, and travel. Devices such as Roche’s CoaguChek INRange allow patients to self-test anywhere, anytime, which reducing dependency on clinical visits, thereby driving the market growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on product type, the point of care coagulation testing products market is bifurcated into instruments and consumables. The instruments segment accounted for a 63% market share in 2024 and is projected for significant growth to reach USD 3.3 billion by 2034.
 

• Point-of-care (POC) coagulation testing instruments offers quick and rapid results, which significantly helps in reducing the turnaround time compared to traditional lab testing. This is specifically important in emergency settings, such as stroke management or trauma care, where immediate clotting status assessment can be needed. For example, Siemens Xprecia Stride provide INR results within minutes, allowing for quick adjustments in anticoagulation therapy and other medical interventions.
   
• In addition to this, by offering fast and accurate coagulation measurements, POC testing devices contributes to better patient outcomes. Whereas early detection of clotting abnormalities helps in timely interventions, minimizes the risks of complications such as excessive bleeding or thromboembolic events.
   
• For instance, the CoaguChek XS System by Roche is widely used in clinics and home settings to help patients on warfarin therapy monitor their INR levels, ensuring optimal anticoagulant dosing and preventing adverse effects.
   
• Further, many POC coagulation testing instruments are compacted and lightweight, which makes them highly portable and convenient for use in various healthcare settings. Such modern POC instruments can be easily used at the patient’s bedside, in emergency rooms, ambulances, outpatient clinics, or even in home healthcare environments. Thus, these advantages are driving growth of the market.
   

Based on end use, the point of care coagulation testing products market is segmented into hospitals, diagnostic centers, home-care settings, and other end users. The hospitals segment dominated the market with the largest revenue of USD 1.1 billion in 2024.
 

• The growth of the segment is owing to the ability of the hospital to manage large volume of patients requiring coagulation testing including both inpatient and outpatient. For instance, hospitals having specialized cardiac and critical care units perform rapid coagulation testing to monitor conditions such as deep vein thrombosis, pulmonary embolism, and stroke.
   
• Further, the rising cases of chronic blood disorders and as well as the hospitalization and visiting rate of patients, fostering the need for effective treatment and diagnostic equipment in the hospital setting to delivery utmost care to the patients in this setting, thereby fostering the growth of the segment.
   
• Additionally, the growing demand for the rapid, bedside treatment to manage conditions such as hemophilia, atrial fibrillation, and others, creating the demand for point of care coagulation testing products in hospitals. Since these advance therapies requires highly skilled personnel which is readily available in the hospital setting, thereby the segment remains in the forefront in the rapidly evolving market.
   

The North America point of care coagulation testing products market is accounted for USD 1 billion revenues in 2024 forecasted to reach USD 1.9 billion by 2034. The U.S. dominated the North America market with the largest revenue of USD 851.4 million in 2023.
 

• This growth is largely attributed to the increasing prevalence of chronic blood disorders in the U.S.
  
   
• For instance, according to the Centers for Disease Control and Prevention (CDC), hemophilia occurs in approximately 1 in 5,617 live male births. There are between 30,000 – 33,000 males suffering with hemophilia in the U.S.  More than half of people were diagnosed with hemophilia A have the severe form. Hemophilia A is four times as common as hemophilia B. Therefore, hemophilia affects all races and ethnic groups.
   
• Additionally, despite a stringent regulatory environment, there is strong support for the approval and commercialization of innovative healthcare solutions such as point of care coagulation testing products.
   
• Moreover, the technological advancements and adoption of the POC coagulation testing products across the country are further boosting the growth of the market in the country.
   

Europe: The point of care coagulation testing products market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The country’s well established healthcare system and the rising demand for accurate and efficient point of care coagulation testing products are the key factors stimulating the growth of the market in the country.
   
• Moreover, the growing aging population base and an increasing awareness early disease detection are further solidifying the growth of point of care coagulation testing products market in the country.
   
• For instance, as per the data from Office for National Statistics, the elderly population of the UK is expected to rise significantly. In 2020, an estimated 2.5% of the total population comprised of people aged 85 and over, by 2040 the figure is projected to reach 4.3% of the total population.
   
• Thus, this demographic shift stimulates the need for high quality POC testing products, specifically for chronic blood disorders, thereby fostering the market growth in the region.
   

Asia Pacific: Japan point of care coagulation testing products market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The country has one of fastest aging population which necessities frequent chronic blood disorders screening and monitoring. Point of care coagulation testing products provides an effective and convenient option for diagnosing disorders, impelling their adoption in the country.
   
• For example, in 2023 projections from the World Economic Forum revealed that 1 in 10 people in Japan are aged 80 years and above which is about one-third of the population.
   
• Thus, this demographic shift has created awareness among the healthcare providers and policy makers for the need of effective strategies to address age related susceptibility to the disorders, thereby escalating the market growth.
   

Middle East and Africa: The point of care coagulation testing products market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia’s advance healthcare infrastructure and rising investment in advanced healthcare technologies create opening for the development and adoption of advanced point of care coagulation testing products tailored to the country’s patient specific needs.
   
• Further, the rising awareness regarding the importance of early and accurate blood-related diseases diagnosis across various age group of individuals in the country, further propelling the market growth.
   

 Point of Care Coagulation Testing Products Market Share

The top 4 players of the market account for approximately 40% of the market share which includes companies such as Abbott Laboratories, F. Hoffmann-La Roche, Sysmex Corporation, and Thermo Fisher Scientific, among others. These companies maintain their dominance in the market through innovative product launches, extensive distribution networks and strong regulatory approval.
 

Moreover, strategic partnerships with research institutes, and government agencies play a primary role in advancing the development of new point of care coagulation testing products and getting the necessary permits. The development of public awareness about infectious diseases and its health impact through the social media platform, will encourage more individuals to seek the early diagnosis and treatment, enabling market players to strengthen their position in this growing sector.
 

Point of Care Coagulation Testing Products Market Companies

Some of the eminent market participants operating in the point of care coagulation testing products industry include:

• Abbott Laboratories
• Alere
• A&T Corporation
• Diagnostica Stago Sas
• F. Hoffmann-La Roche
• Genrui Biotech
• Helena Laboratories
• Horiba
• Medtronic
• Nihon Kohden Corporation
• Micropoint Biosciences
• Maccura Biotechnology
• Sysmex Corporation
• Siemens Healthineers
• Thermo Fisher Scientific

• F. Hoffmann-La Roche has robust geographical presence which enables it to enhance its market reach. F. Hoffmann-La Roche has presence over 100 countries and with the support of a large network of distributors, thus involving a strong distribution network.
   
• Abbott Laboratories has strong product portfolio leading to larger adoption and significant market expansion. Abbott provides a products pertaining to point of care coagulation testing products such as i-STAT PT/INR system, among others.
   
• Thermo Fisher Scientific has strong global workforce of approximately 122,000 employees, which enables the company to drive innovation, and deliver high-quality solutions.
   

Point of Care Coagulation Testing Products Industry News:

• In February 2021, Siemens Healthineers and Sysmex Corporation extended their global agreement for hemostasis products, including Sysmex's CN-Series automated blood coagulation analyzers. This partnership enhanced coagulation testing for mid and high-volume laboratories and expanded Siemens Healthineers' distribution of Sysmex CN Systems, driving market growth.
   

The point of care coagulation testing products market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Prothrombin time testing products
• Activated clotting time (ACT/APTT) testing products
• Platelet count
• D-dimer test
• Others test types

Market, By Product Type

• Instruments
• Consumables

Market, By End Use

• Hospitals
• Diagnostic centers
• Home care settings
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE